Formulation containing novel anti-inflammatory androstane derivative
US6750210B2 · kind B2 · utility
12Cited by
41References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 4, 2002 |
| Grant date | Jun 15, 2004 |
| Priority date | — |
| Expiry date | Mar 2, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07J31/006
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is provided a pharmaceutical aerosol formulation comprising (i) a compound of formula (I) or a solvate thereof as medicament, (ii) a liquified hydrofluoroalkane (HFA) gas as propellant; and characterized in that the compound of formula (I) or a solvate thereof is completely dissolved in the formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.